<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03144947</url>
  </required_header>
  <id_info>
    <org_study_id>GOIRC-01-2016</org_study_id>
    <nct_id>NCT03144947</nct_id>
  </id_info>
  <brief_title>Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in Patients With HER2-positive Breast Cancer</brief_title>
  <acronym>IMMUN-HER</acronym>
  <official_title>Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients With Operable or Locally Advanced/Inflammatory HER2-positive Breast Cancer (ImmunHER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Oncologico Italiano di Ricerca Clinica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Parma: Department of Biomedical, Biotechnological and Translational Sciences, Pathological Anatomy and Histology Unit</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Parma:Laboratory of Viral Immunopathology, Unit of Infectious Diseases and Hepatology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Parma:Statistica medica ed epidemiologia clinica-UO Ricerca e Innovazione</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clirest s.r.l.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mipharm SpA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arithmos srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Temas srl</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Oncologico Italiano di Ricerca Clinica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of
      Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients with Operable or Locally Advanced
      /Inflammatory HER2-positive Breast Cancer (ImmunHER)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women with histologically confirmed HER2-positive breast cancer with locally advanced,
      inflammatory,or early stage tumor (either greater than 2 cm in diameter or node positive)
      with no evidence of metastatic disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non comparative, multi-center, open-label, neoadjuvant, randomized study, the purpose of randomization is to reduce bias owing to patient selection into treatments groups.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor Infiltrating lymphocites (TIL) rate on residual disease after either IV trastuzumab or SC trastuzumab (see related paragraph)</measure>
    <time_frame>6 months after last patient in</time_frame>
    <description>stromal lymphocytes will be scored quantitatively on H&amp;E stained whole-tumor slides as a continuous variable expressed as stromal percentage area within the tumor boundaries. For tumors with heterogeneous TILs, median values will be calculated from multiple counts from different tumor areas. Intra-epithelial TILs will also be recorded as well as tertiary lymphoid structures. Tumor regression will be scored based on recommended criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Associations between biomarkers (TIL, Tumor specific lymphocyte cell activity (TLA), and Fc-gamma-R polymorphisms) and between each biomarker with clinical outcome variables.</measure>
    <time_frame>at baseline, 6 months and 5 years after last patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of toxicity Events: frequency of moderate and severe toxicity events and drop-out rate due to theraphy related toxicity (NCICommon Toxicity Criteria v 4.0)</measure>
    <time_frame>3.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HRQOL during study treatment based on FACT-B</measure>
    <time_frame>at baseline, and 6 months after last patient in</time_frame>
    <description>mean FACT-B scores assessed at enrolment and mean FACT-B scores assessed before surgery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete pathological response rate by treatment arm</measure>
    <time_frame>6 months after last patient in</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year disease-free survival by treatment arm between treatment arms</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cancer, Breast</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
After surgery, study patients will receive trastuzumab IV x 14 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles. After surgery, study patients will receive trastuzumab SC x 14 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab IV</intervention_name>
    <description>Pre-randomization phase:
FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles
Post-randomization phase:
Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase.</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Herceptin-150 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab SC</intervention_name>
    <description>Pre-randomization phase:
FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;
Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase.</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Herceptin-600 mg/5 mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pertuzumab</intervention_name>
    <description>pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>PerJeta 420 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Docetaxel 20 MG/ML</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated, infiltrating primary breast cancer with locally advanced,
             inflammatory, or early stage tumor (either greater than 2 cm in diameter or node
             positive) with no evidence of metastatic disease.

          -  HER2 positivity (either immunohistochemistry 3+ or fluorescent in situ hybridization
             amplification).

          -  Age 18 or older.

          -  Eastern Cooperative Oncology Group performance status of 0 to 1.

          -  Availability of tumor tissue for biologic and molecular examination before starting
             primary treatment.

          -  Left ventricular ejection fraction within the institutional range of normal.

          -  Normal organ and marrow function.

          -  Adequate contraception methods for women of childbearing potential.

          -  Prior diagnosis of cancer is allowed as long as patient is free of disease and has
             been off treatment for the prior malignancy for a minimal interval of 3 years.

          -  Written informed consent.

        Exclusion Criteria:

          -  Either stage I or IV breast cancer.

          -  Prior trastuzumab or pertuzumab.

          -  Any prior chemotherapy.

          -  Treatment with any other investigational agent, or participation in another clinical
             trial within 28 days prior to enrolment.

          -  Undergone major surgery (e.g., intrathoracic, intra-abdominal or intra-pelvic) 4 weeks
             prior to starting study drug or who have not recovered from side effects of such
             surgery.

          -  Breast radiotherapy prior to starting study.

          -  Known hypersensitivity to the investigational drugs or any of their excipients.

          -  Evidence of any disease, neurological or metabolic dysfunction, physical examination
             finding or laboratory finding giving reasonable suspicion of a disease or condition
             that contraindicates the use of an GOIRC-01-2016 ImmunHER Protocol Version 1.0, 11
             April 2016 Page 6 of 140 investigational drug, or puts the patient at high risk for
             treatment-related complications.

          -  Moderate/severe hepatic impairment (Child- Pugh B/C).

          -  Uncontrolled inter-current illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Concurrent malignancy or malignancy within 3 years prior to study enrollment, with the
             exception of adequately treated basal cell carcinoma, squamous cell carcinoma or other
             non-melanomatous skin cancer, or insitu carcinoma of the uterine cervix.

          -  Pregnancy or breastfeeding (breast feeding should be discontinued to be enrolled in
             the study).

          -  Women of childbearing potential that refusal to adopt adequate contraceptive measures.

          -  Unwilling or unable to comply with the protocol. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UO di Oncologia Ematologia, Azienda Ospedaliero Universitaria di Ferrara</name>
      <address>
        <city>Cona</city>
        <state>Ferrara</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Frassoldati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica, Azienda ULSS21 di Legnago</name>
      <address>
        <city>Legnago</city>
        <state>Verona</state>
        <zip>37045</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Bonetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, Ospedale Sacro Cuore - Don Calabria - Negrar (VR)</name>
      <address>
        <city>Negrar</city>
        <state>Verona</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Stefania Gori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia-A.O. PAPA GIOVANNI XXIII Bergamo</name>
      <address>
        <city>Bergamo</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Zambelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SSD di Oncologia Medica Addarii, Policlinico S. Orsola-Malpighi,</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Zamagni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC di Oncologia. Azienda USL di Bologna, Ospedale Bellaria,</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alba Brandes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Oncologia Medica - Ospedale di Bolzano,</name>
      <address>
        <city>Bolzano</city>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Claudio Graiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Breast Unit Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Edda Simoncini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigational Clinical Oncology - INCOIRCCS-Fondazione del Piemonte per l'Oncologia (FPO)</name>
      <address>
        <city>Candiolo (TO)</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Filippo Montemurro, DM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chirurgia generale ad indirizzo senologico-Breast Unit Azienda Istituti Ospitalieri di Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Daniele Generali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna e Specialità Mediche (DI.M.I.)-Università di Genova Clinica di Medicina Interna ad indirizzo oncologico</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Alberto Ballestrieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, IRST. Istituto Scientifico Romagnolo per lo studio e la cura dei Tumori, IRCCS di Meldola</name>
      <address>
        <city>Meldola (FC)</city>
        <zip>47014</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Rocca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Mediche e Chirurgiche, Materno Infantili e dell'adulto. Policlinico di Modena</name>
      <address>
        <city>Modena</city>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Luca Moscetti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SC di Oncologia Medica, A.O. San Gerardo</name>
      <address>
        <city>Monza (MB)</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Marina Cazzaniga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Parma, UOC di Oncologia Medica</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Antonio Musolino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia e Ematologia, UO di Oncologia Medica Azienda USL di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Cavanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di OncologiaIRCCS- Istituto in Tecnologie Avanzate e Modelli Assistenziali in Oncologia Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Giancarlo Bisagni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO di Oncologia. Azienda USL di Rimini</name>
      <address>
        <city>Rimini</city>
        <zip>47923</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Lorenzo Gianni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Day Hospital, Ospedale di Sassuolo</name>
      <address>
        <city>Sassuolo (MO)</city>
        <zip>41049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Partesotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. di Oncologia Medica PO &quot;S. Chiara&quot;</name>
      <address>
        <city>Trento</city>
        <zip>38122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Antonella Ferro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Az. Ospedaliera di Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todeschini</last_name>
      <email>infogoirc@libero.it</email>
    </contact>
    <investigator>
      <last_name>Emilio Bria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>May 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2017</study_first_posted>
  <last_update_submitted>May 4, 2017</last_update_submitted>
  <last_update_submitted_qc>May 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

